<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02692755</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1396</org_study_id>
    <nct_id>NCT02692755</nct_id>
  </id_info>
  <brief_title>Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer</brief_title>
  <acronym>PALINA</acronym>
  <official_title>Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the hematological safety of palbociclib with letrozole and
      fulvestrant in African American women with hormone receptor positive HER2 negative advanced
      breast cancer. Hematological safety is a composite endpoint of episodes of febrile
      neutropenia and treatment discontinuation due to neutropenia according to current
      recommendations for management of neutropenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to assess the rate of completion of planned oncology therapy in the
      absence of a hematological event defined as episodes of febrile neutropenia and treatment
      discontinuation due to neutropenia. A completion rate of 80% is considered of clinical
      relevance as to benefit breast cancer patients who are at a higher risk of having ethnic
      neutropenia where as a completion rate of 60% is considered poor and to justify additional
      safety studies. A two stage design with a total of 35 patients is used to test if the
      completion rate is at least 80% versus if it is below 60% with 80% power at a significance
      level of 5%.

      An exact confidence interval of the completion rate will be calculated. Investigators
      estimate there will be no more than a 10% rate of febrile neutropenia. Due to the small
      sample size, the analysis of secondary endpoints will be descriptive and will not include
      specific hypothesis testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who complete planned oncologic therapy without the development of a hematological event</measure>
    <time_frame>12 months</time_frame>
    <description>For study purpose febrile neutropenia will be defined according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0: &quot;ANC less than 1000/mm3 with a single temperature of &gt;38.3 degrees Celsius (101 degrees Fahrenheit) or a sustained temperature of 38 degrees Celsius (100.4 degrees Fahrenheit) for more than one hour.&quot;
Planned oncology therapy is defined as completion of one year of therapy for advanced breast cancer in the absence of disease progression or cessation of study drug due to progressive disease or non-hematological toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who required dose delays in palbociclib attributed to neutropenia.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who required dose reductions in palbociclib therapy attributed to neutropenia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR), for those with evaluable disease, defined as the percentage of patients who achieved complete response, partial response and stable disease</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hormone Receptor Positive HER-2 Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single ARM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib + Letrozole or Fulvestrant</intervention_name>
    <description>Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months</description>
    <arm_group_label>Single ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Self-identified Black, African or African American women of ≥ 18 years of age with
             proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or
             metastatic disease)

          2. ER-positive and/or PgR-positive tumor based on local laboratory results

          3. HER2-negative breast cancer based on local laboratory results (test to be used as per
             local practice)

          4. Patients must be appropriate candidates for letrozole or fulvestrant therapy

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          6. Adequate bone marrow function:

               -  Absolute Neutrophil Count (ANC) ≥ 1,000/mm3 (1.0 x 109/L);

               -  Platelets ≥100,000/mm3 (100 x 109/L);

               -  Hemoglobin ≥9 g/dL (90 g/L).

        Exclusion Criteria:

          1. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4

          2. Active uncontrolled or symptomatic brain metastases. Previously treated and clinically
             stable, as per Investigator's judgment, brain metastases are permitted.

          3. Previous CDK4/6 inhibitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filipa Lynce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar Georgetown University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nellie Novielli, RN</last_name>
    <phone>2027843923</phone>
    <email>noviella@georgetown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Castle, RN</last_name>
    <phone>2026872209</phone>
    <email>bickmorj@georgetown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nellie Novielli, RN</last_name>
      <phone>202-784-3923</phone>
      <email>noviella@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Castle, RN</last_name>
      <phone>2026872209</phone>
      <email>bickmorj@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Filipa Lynce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Okobi</last_name>
      <phone>202-877-8156</phone>
    </contact>
    <investigator>
      <last_name>Christopher Gallagher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Olwen Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Rector</last_name>
      <phone>410-261-8151</phone>
    </contact>
    <investigator>
      <last_name>Mahsa Mohebtash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Good Samaritan Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Rector</last_name>
      <phone>410-261-8151</phone>
    </contact>
    <investigator>
      <last_name>Lois Kamugisha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maysa Abu-Khalaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.</citation>
    <PMID>20610543</PMID>
  </reference>
  <reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717.</citation>
    <PMID>15894097</PMID>
  </reference>
  <reference>
    <citation>Wood WC, Muss HB, Solin LJ, Olopade OI. Malignant Tumors of the Breast. In: DeVita VT Jr, Hellmann S, Rosenberg SA, editors. Cancer, Principle and Practice of Oncology, 7thEdition, Lippincott Williams and Wilkins; 2005; 1415-1477.</citation>
  </reference>
  <reference>
    <citation>Leung BS, Potter AH. Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population. J Cell Biochem. 1987 Jul;34(3):213-25.</citation>
    <PMID>3611201</PMID>
  </reference>
  <reference>
    <citation>Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 1983 Sep;43(9):3998-4006.</citation>
    <PMID>6871841</PMID>
  </reference>
  <reference>
    <citation>Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003 Jun 1;21(11):2101-9.</citation>
    <PMID>12775735</PMID>
  </reference>
  <reference>
    <citation>Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.</citation>
    <PMID>19874578</PMID>
  </reference>
  <reference>
    <citation>Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011 Jun 7;104(12):1862-8. doi: 10.1038/bjc.2011.177. Epub 2011 May 24.</citation>
    <PMID>21610706</PMID>
  </reference>
  <reference>
    <citation>Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD, O'Dwyer PJ, Schwartz GK. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012 Jan 15;18(2):568-76. doi: 10.1158/1078-0432.CCR-11-0509. Epub 2011 Nov 16.</citation>
    <PMID>22090362</PMID>
  </reference>
  <reference>
    <citation>DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11.</citation>
    <PMID>25501126</PMID>
  </reference>
  <reference>
    <citation>Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16.</citation>
    <PMID>25524798</PMID>
  </reference>
  <reference>
    <citation>A study of Palbociclib (PD-0332991) + letrozole vs. letrozole for first line treatment of postmenopausal women with ER/HER2- advanced breast cancer (PALOMA-2). Available at: https://clinicaltrials.gov/ct2/show/NCT01740427. Accessed on August 9, 2015</citation>
  </reference>
  <reference>
    <citation>Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Oct 22;373(17):1672-3. doi: 10.1056/NEJMc1510345.</citation>
    <PMID>26488700</PMID>
  </reference>
  <reference>
    <citation>NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research - Amended, October, 2001</citation>
  </reference>
  <reference>
    <citation>Chen MS Jr, Lara PN, Dang JH, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer. 2014 Apr 1;120 Suppl 7:1091-6. doi: 10.1002/cncr.28575. Review.</citation>
    <PMID>24643646</PMID>
  </reference>
  <reference>
    <citation>Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007 Apr 3;146(7):486-92.</citation>
    <PMID>17404350</PMID>
  </reference>
  <reference>
    <citation>Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, Mullikin J, Hsueh WC, Cheng CY, Coresh J, Boerwinkle E, Li M, Waliszewska A, Neubauer J, Li R, Leak TS, Ekunwe L, Files JC, Hardy CL, Zmuda JM, Taylor HA, Ziv E, Harris TB, Wilson JG. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet. 2009 Jan;5(1):e1000360. doi: 10.1371/journal.pgen.1000360. Epub 2009 Jan 30.</citation>
    <PMID>19180233</PMID>
  </reference>
  <reference>
    <citation>Hsieh MM, Tisdale JF, Rodgers GP, Young NS, Trimble EL, Little RF. Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol. 2010 Apr 1;28(10):1633-7. doi: 10.1200/JCO.2009.24.3881. Epub 2010 Mar 1.</citation>
    <PMID>20194862</PMID>
  </reference>
  <reference>
    <citation>Hershman D, Weinberg M, Rosner Z, Alexis K, Tiersten A, Grann VR, Troxel A, Neugut AI. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst. 2003 Oct 15;95(20):1545-8.</citation>
    <PMID>14559877</PMID>
  </reference>
  <reference>
    <citation>Shajahan-Haq AN, Cheema MS, Clarke R. Application of metabolomics in drug resistant breast cancer research. Metabolites. 2015 Feb 16;5(1):100-18. doi: 10.3390/metabo5010100. Review.</citation>
    <PMID>25693144</PMID>
  </reference>
  <reference>
    <citation>Nowicki S, Gottlieb E. Oncometabolites: tailoring our genes. FEBS J. 2015 Aug;282(15):2796-805. doi: 10.1111/febs.13295. Epub 2015 Apr 30. Review.</citation>
    <PMID>25864878</PMID>
  </reference>
  <reference>
    <citation>Günther UL. Metabolomics Biomarkers for Breast Cancer. Pathobiology. 2015 Sep;82(3-4):153-65. doi: 10.1159/000430844. Epub 2015 Aug 31. Review.</citation>
    <PMID>26330356</PMID>
  </reference>
  <reference>
    <citation>Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, Eltayeb AE, Demas DM, Warri AM, Facey CO, Hilakivi-Clarke LA, Clarke R. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer. 2014 Oct 23;13:239. doi: 10.1186/1476-4598-13-239.</citation>
    <PMID>25339305</PMID>
  </reference>
  <reference>
    <citation>Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010 Nov 1;70(21):8309-18. doi: 10.1158/0008-5472.CAN-10-1319. Epub 2010 Oct 19.</citation>
    <PMID>20959483</PMID>
  </reference>
  <reference>
    <citation>Lowry MC, Gallagher WM, O'Driscoll L. The role of exomes in Breast Cancer. Clin Chem 2015 Oct 14. Epub ahead of print.</citation>
  </reference>
  <reference>
    <citation>Yu S, Cao H, Shen B, Feng J. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget. 2015 Nov 10;6(35):37151-68. doi: 10.18632/oncotarget.6022. Review.</citation>
    <PMID>26452221</PMID>
  </reference>
  <reference>
    <citation>Yu DD, Wu Y, Zhang XH, Lv MM, Chen WX, Chen X, Yang SJ, Shen H, Zhong SL, Tang JH, Zhao JH. Exosomes from adriamycin-resistant breast cancer cells transmit drug resistance partly by delivering miR-222. Tumour Biol. 2016 Mar;37(3):3227-35. doi: 10.1007/s13277-015-4161-0. Epub 2015 Oct 2.</citation>
    <PMID>26432333</PMID>
  </reference>
  <reference>
    <citation>Lv MM, Zhu XY, Chen WX, Zhong SL, Hu Q, Ma TF, Zhang J, Chen L, Tang JH, Zhao JH. Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 2014 Nov;35(11):10773-9. doi: 10.1007/s13277-014-2377-z. Epub 2014 Jul 31.</citation>
    <PMID>25077924</PMID>
  </reference>
  <reference>
    <citation>Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull. 2007 Sep;33(5):1221-4. Epub 2006 Dec 14.</citation>
    <PMID>17170061</PMID>
  </reference>
  <reference>
    <citation>Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, Di Poto C, Wang J, Goerlitz D, Luo Y, Cheema AK, Sarhan N, Soliman H, Tadesse MG, Ziada DH, Ressom HW. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res. 2012 Dec 7;11(12):5914-23. doi: 10.1021/pr300673x. Epub 2012 Nov 1.</citation>
    <PMID>23078175</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>African American</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

